Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)-Reference-Cited by-同舟云学术

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)

Published:2019-11-15 Issue:2 Volume:18 Page:341-351
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Klamroth Robert¹,Feistritzer Clemens²,Friedrich Ute³,Lentz Steven R.⁴,Reichwald Kirsten⁵,Zak Marek³,Chowdary Pratima⁶

Affiliation:

1. Department of Internal Medicine Hemophilia Treatment CentreVivantes Klinikum im Friedrichshain Berlin Germany

2. Internal Medicine V—Hematology and Oncology Medical University of Innsbruck Innsbruck Austria

3. Novo Nordisk Søborg Denmark

4. The University of Iowa Carver College of Medicine Iowa City IA USA

5. Novo Nordisk Måløv Denmark

6. KD Haemophilia and Thrombosis Centre Royal Free London NHS Foundation Trust London UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14660

Reference51 articles.

1. The Potential Close Future of Hemophilia Treatment - Gene Therapy, TFPI Inhibition, Antithrombin Silencing, and Mimicking Factor VIII with an Engineered Antibody

2. Prophylaxis in haemophilia should be life‐long;Makris M;Blood Transfus,2012

3. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project

4. Prevention of arthropathy in haemophilia: prophylaxis

5. Past, present and future of hemophilia: a narrative review

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Binding Promiscuity of Therapeutic Factor VIII;Thrombosis and Haemostasis;2024-07-01

2. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state;Journal of Thrombosis and Haemostasis;2024-02

3. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment;Seminars in Thrombosis and Hemostasis;2024-01-15

4. Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A;Haemophilia;2023-11-17

5. Factor IX administration in the skin primes inhibitor formation and sensitizes hemophilia B mice to systemic factor IX administration;Research and Practice in Thrombosis and Haemostasis;2023-11